ADVM: Adverum Biotechnologies Inc. Company Short-Term Debt

How can the delivery of fragile drugs at ultra-low temperatures be ensured? Adverum Biotechnologies addresses this through validated cold chains, creating unique gene therapies to combat macular dystrophy. The company currently relies on investments and clinical trials. Credit obligations of up to one year, where GURU.Markets data is illustrated on this chart, show that the indicator value is 0.00.

This indicator determines the issuer's solvency by aggregating all liabilities with a maturity horizon of up to twelve months to assess refinancing risks and interest rate sensitivity. By analyzing the history of short-term debt fluctuations, an investor can gauge the financial cushion of Adverum Biotechnologies (ADVM), which is critical when hiring expensive clinical operations executives and retaining key gene vector developers through stock option programs.